Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 16, Issue 10, 2002, Pages 1743-1750

  Ansari, A ^b   Hassan, C ^b   Duley, J ^b   Marinaki, A ^b   Shobowale Bakre, E M ^b   Seed, P ^a   Meenan, J ^b   Yim, A ^b   Sanderson, J ^b,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; THIOPURINE METHYLTRANSFERASE;

ABDOMINAL PAIN; ADULT; ARTICLE; CROHN DISEASE; DRUG TOLERABILITY; DRUG TOXICITY; ENTERITIS; ENZYME ACTIVITY; ENZYME DEFICIENCY; FEMALE; FLU LIKE SYNDROME; GENE MUTATION; GENOTYPE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NEUTROPENIA; PANCREATITIS; PHENOTYPE; PRIORITY JOURNAL; RASH; ULCERATIVE COLITIS;

ADULT; AZATHIOPRINE; BIOLOGICAL MARKERS; ERYTHROCYTES; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE COUNT; LOGISTIC MODELS; MALE; METHYLTRANSFERASES; MIDDLE AGED; ODDS RATIO; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 0036790212     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2002.01353.x     Document Type: Article

References (29)

1. Bouhnik Y, Lémann M, Mary JY. et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996: 347: 215-9.
2. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short and long-term toxicity. Ann Intern Med 1989: 111: 641-9.
3. George J. Present DH. Pou R. et al. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 1996: 91: 1711-4.
4. Korelitz BI. Adler DJ. Mendelsohn RA. et al. Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease. Am J Gastroenterol 1993: 88: 1198-205.
5. Welch J. Lennard L. Morton GC. et al. Ther Drug Monit 1997: 19(4): 382-5.
6. Grant DM, Tang BK. Kalow W. Variability in caffeine metabolism. Clin Pharmacol Ther 1983: 33: 591-602.
7. Weinshilboum R. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos 2001: 29(4 Part 2): 601-5.
8. Hon YY. Fessing MY. Pui CH, et al. Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet 1999: 8: 371-6.
9. Ameway MM. Collie-Duguid ESR. Powrie RH. et al. Thiopurine S-methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet 1999: 8: 367-70.
10. Lennard L, Lilleyman JS, Van Loon J, et al. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990: 336: 225-9.
11. Dubinsky MC. Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000: 118: 705-13.
12. Chocair PR. Duley JA. Simmonds HA. et al. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation 1992: 53: 1051-6.
13. Weinshilboum RM. Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980: 32: 651-62.
14. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997: 126: 608-14.
15. Cornfield J. A statistical problem arising from retrospective studies. In: Neyman J. ed. Proceedings of the Third Berkeley Symposium. Vol. 4. Berkeley. CA: University of California Press. 1956: 135-48.
16. Greenland S. An application of logistic models to the analysis of ordinal response. Biometr J 1985: 27: 189-97.
17. Stolk JN. Boerbooms AM. de Abreu RA. et al. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis Rheum 1998: 41: 1858-66.
18. Lennard L. Davies HA. Lilleyman JS. Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia? Br J Cancer 1993: 68(1): 186-90.
19. Colombel JF. Ferrari N, Debuysere H. et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000: 118: 1025-30.
20. McGovern DP. Shobowale-Bakre EM. Duley J. et al. Early azathioprine intolerance in IBD patients is imidazole-related and independent of thiopurine methyl transferase activity. Gastroenterology 2000: 4927: A890(Abstract).
21. Ansari AR, Escudier M, Shobowala-Barkre E, et al. Responses to low dose azathioprine in patients with heterozygous thiopurine methyl transferase deficiency. Gastroenterology 2001: 3175: A639(Abstract).
22. Cuffari C. Hunt S. Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patient with inflammatory bowel disease. Gut 2001: 48(5): 642-6.
23. Lowry PW. Franklin CL. Weaver AL. et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001: 49: 665-70.
24. McLeod HL. Relling MV. Liu Q. et al. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia, Blood 1995: 85: 1897-902.
25. Szumlanski CL. Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995: 39(4): 456-9.
26. Lowry PW. Franklin CL. Weaver AL. et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 2001: 49(5): 656-64.
27. Dewit O. Vanheuverzwyn R. Desager JP. Horsmans Y. Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease. Aliment Pharmacol Ther 2002: 16(1): 79-85.
28. Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998: 115(4): 813-21.
29. Lennard L. Van Loon JA. Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989: 46: 149-54.